Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.
Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.
Active, not recruiting · NCT05457010 · Registry updated 2026-10-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome. | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 | 2026-10-02 | NCT05457010 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Arcellx, Inc. | 5 |
| Kite, A Gilead Company | 27 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope | Duarte | United States | 238 |
| Dana Farber Cancer Institute | Boston | United States | 300 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Montefiore Einstein Cancer Center | New Rochelle | United States | 1 |
| The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | United States | 1 |